HALIFAX, Dec. 2, 2013 /CNW/ - MedMira, Inc. (MedMira) (TSXV: MIR), a
developer of rapid diagnostic technology and solutions, today announced
that Dan Frid, the Company's Chief Financial Officer, will leave the
Company effective December 6, 2013, to pursue other professional
opportunities. Frid has served as MedMira's CFO since July 2010, with
overall responsibility for financial and accounting operations,
strategic fiscal planning, accountability and analysis, and contributed
to various corporate support and administrative functions.
"We would like to thank Dan for his leadership and contributions to the
Company," said Hermes Chan, Chief Executive Officer of MedMira Inc.
"Dan has been committed to this organization and has added to the
strength of its financial position. We wish him all the best in his
The Company has identified a new CFO and a detailed announcement will be
MedMira is the leading developer and manufacturer of flow-through rapid
diagnostics and technologies. MedMira is the only Canadian company to
be awarded US Army contracts for the development of rapid tests for HIV
and Hepatitis viruses. The Company's testing solutions provide
hospitals, labs, clinics and individuals with reliable, rapid diagnosis
for diseases such as HIV and hepatitis C in just three minutes. The
Company's tests are sold under the Reveal®, Multiplo™ and Miriad brands
in global markets. MedMira is located in Halifax, Nova Scotia, Canada. www.medmira.com.
This news release contains forward-looking statements, including
statements relating to growth in the Company's business, earnings and
profitability, and trends in demand for the Company's products, which
involve risk and uncertainties and reflect the Company's current
expectation regarding future events including statements regarding
possible future growth and new business opportunities. Actual events
could materially differ from those projected herein and depend on a
number of factors including, but not limited to, changing market
conditions, successful and timely completion of clinical studies,
uncertainties related to the regulatory approval process, establishment
of corporate alliances and other risks detailed from time to time in
the company quarterly filings.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
SOURCE: MEDMIRA INC.
For further information:
Andrea Young, Corporate Communications